Kyntra Bio, Inc. KYNB
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Kyntra Bio, Inc. (KYNB) is a healthcare company listed in the US with a market value of about $14M. In the twelve months to June 30, 2026 it had revenue of $5M and net income of $183M, a net margin of 3967.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.1, a 5-year average ROIC of -211%.
About Kyntra Bio
Kyntra Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $138M in 2014 to $30M in 2024, a decline of about 14.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 8% over three years (dilution for shareholders).
Score: 1.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | — | $30M | $47M | $141M | $235M | $176M | $257M | $213M | $131M | $183M |
| Net income | $183M | $183M | -$48M | -$284M | -$294M | -$290M | -$189M | -$77M | -$86M | -$121M | -$58M |
| Free cash flow | -$38M | -$5M | -$138M | -$318M | -$150M | -$87M | $78M | -$84M | -$84M | -$75M | $6M |
| EPS (diluted) | $45.28 | $45.37 | $-11.89 | $-73.00 | $-78.50 | $-78.50 | $-52.75 | $-22.25 | $-25.75 | $-41.50 | $-23.25 |
| Net margin | 3967.8% | — | -160.6% | -607.3% | -208.7% | -123.2% | -107.4% | -30.0% | -40.6% | -92.3% | -31.7% |
| ROIC | — | — | — | — | -347.5% | -73.8% | -35.7% | -13.6% | -13.5% | -17.5% | -32.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Kyntra Bio’s P/E ratio?
About 0.1, based on the last twelve months of diluted earnings per share.
Does Kyntra Bio pay a dividend?
Not currently.
Is Kyntra Bio a good stock to buy?
We do not give buy or sell advice. Kyntra Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.